Weight-loss drug battle: Who are the latest players involved
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...
Ozempic maker says its Australian market could be half the population
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...
Hims & Hers: AI-Powered Healthcare Disruption
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...
Hims & Hers to Discontinue Dermatology Line Apostrophe
Hims & Hers Health will shut down Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being shut down to “simplify its (company’s) dermatology ...
Shocking stories of people who went blind after taking Ozempic and Mounjaro
Weight loss drugs like Ozempic, while transformative in combating obesity, have been linked to irreversible vision impairment ...
pharmaphorum14h
Novo Nordisk forges close ties with biotech VC Flagship
The partnership with Flagship will bring Novo Nordisk into closer contact with the VC's portfolio of 41 biotech companies, with the aim of creating a portfolio of "transformational" medicines for ...